Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

Karuna Therapeutics: Investors: Alexis Smith 518-338-8990 [email protected] Media: Bob Josefsberg [email protected] 646-734-3584 Goldfinch Bio: Kyle Kuvalanka [email protected] ...

Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, ...

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year. The company has, as of the fourth quarter, $1.1 billion in cash, it said.

Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.

Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster "If successful, we believe KarXT could generate more than $1 billion in U.S. schizophrenia sales," wrote analyst Paul Matteis of ...

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today ...

Karuna Therapeutics IPO in July '19 raised $102.6m at list price of $16.00. Company focused on developing novel therapeutics to treat disabling neuropsychiatric conditions such as schizophrenia ...

Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: These 12 analysts have an average price target of $281.25 versus the current price of ...

Karuna Therapeutics, Inc. and GFB, LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global ...

Over the past 3 months, 8 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...